Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer

Commentary
Video

Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.

Reshma L. Mahtani, DO, spoke with CancerNetwork® about the background of and key findings from her real-world pilot study assessing the implementation of a novel pharmacist-directed point-of-care resource in community and academy oncology settings for patients undergoing infusion therapy for metastatic breast cancer. These findings were highlighted as part of a publication only abstract at the 2025 American Society of Clinical Oncology Annual Meeting.

According to Mahtani, chief of breast medical oncology at Miami Cancer Institute of Baptist Health South Florida, care teams who administer infusion therapies to patients with metastatic breast cancer may experience challenges such as limited collaboration and inconsistent management protocols. The investigational point-of-care initiative, which consisted of regional workshops intended to facilitate the development of evidence-based strategies for managing infusions, demonstrated “striking” improvements in provider confidence, adverse effect (AE) monitoring, and other outcomes, Mahtani said. Based on these results, Mahtani emphasized that providing a targeted tool for pharmacists could be a “game-changer” for optimizing the delivery of infusion therapies while improving patient outcomes.

Transcript:

The rationale for this work stemmed from the growing complexity of managing infusion-based therapies for patients with metastatic breast cancer. These treatments, as we know, require careful coordination across the care team to ensure safe dosing, timely monitoring, and proactive management of [AEs]. However, in real-world settings, especially across diverse academic and community practices, providers often face barriers like limited collaboration, difficulty staying [up to date] with evolving guidelines, and inconsistent management protocols. This was the rationale for our study, or the background.

The way that we approach this issue is to address the gaps that I just outlined. Our team piloted a pharmacist-directed point-of-care resource that was designed to support infusion therapy management. The way we accomplished this was through regional workshops. Multidisciplinary teams in these workshops codeveloped strategies to integrate this resource into their workflows. I would say the results were striking. We saw significant improvements in provider confidence; AE monitoring; and collaboration among pharmacists, oncologists, and infusion staff. Importantly, this translated into fewer reported infusion-related AEs and drug interactions. Our work demonstrates that empowering pharmacists with a targeted tool at the point of care can be a game-changer in optimizing infusion therapy delivery and ultimately improving patient outcomes.

Reference

Mahtani R, Bardia A, Tolaney S, et al. Improving infusion therapy management in metastatic breast cancer: real-world pilot study of a new pharmacy resource. Presented at: 2025 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025; Chicago, IL. Abstract e13115.

Recent Videos
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Related Content